(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

The Carlyle Group Inc. (NASDAQ:CG), a global investment firm with a market capitalization of $18.52 billion, has recently ...

BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...

New York State Teachers Retirement System trimmed its position in The Carlyle Group Inc. (NASDAQ:CG – Free Report) by 0.7% during the 4th quarter, HoldingsChannel reports. The firm owned 44,246 shares ...

The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

Carlyle completed the acquisition through a proprietary and exclusive transaction. The investment will come from funds ...

Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...

Carlyle Group Inc. completed its acquisition of a controlling stake in an Indian auto-parts making platform formed by the ...

Through this platform, Carlyle will help Roop and Highway leverage operating synergies, create capabilities and capacities ...